Seagen Gets PGR Nixed Under Fintiv In Rehearing Decision
Seagen Inc. has persuaded the Patent Trial and Appeal Board on rehearing to deny a challenge from Daiichi Sankyo Inc. and AstraZeneca Pharmaceuticals LP to its cancer antibody patent, with the...To view the full article, register now.
Already a subscriber? Click here to view full article